JDRF T1D Fund — Full Portfolio

vTv Therapeutics is a biopharmaceutical company developing oral, small molecule drugs for diabetes and other chronic diseases.

BiotechDigital HealthMedical DevicesHigh Point, US

RHRudy Howard(Executive Officer)inSHStephen Holcombe(Executive Officer)inLarry Altstiel(Executive Officer)Jeffrey Kindler(Executive Officer, Director)PSPaul Sekhri(Chairman, President, and Chief Executive Officer)inMTMichael Tung(Executive Vice President and Chief Financial Officer)in

Co-investorsSASamsara BioCapital

ADAXION develops deimmunized biologic therapies using its ADAx platform, which incorporates proprietary CD22 ligands to eliminate therapeutic-specific B cells and reduce anti-drug antibody responses.

BiotechDeep Tech

Co-investorsVIVivo Capital

Aera Therapeutics develops genetic medicines using next-generation delivery technologies and precision payloads optimized for specific diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US

FZFeng Zhang, Ph.D.(Scientific Founder & Board Observer)AAAkin Akinc, Ph.D.(Chief Executive Officer & Board Director)

Co-investorsARARCH Venture PartnersLULux CapitalF-F-Prime CapitalGVGV (Google Ventures)NENewpath Partners

Aspect Biosystems develops bioprinted tissue therapeutics using a platform that combines AI-powered bioprinting, computational design tools, therapeutic cells, and biomaterials to create implantable allogeneic tissues.

AI & Machine LearningBiotechLongevity

TMTamer Mohamed(Founder & CEO)inSWSam Wadsworth(Co-founder & Chief Scientific Officer)inSBSimon Beyer(Co-founder & Chief Technology Officer)inLPLeela Paris(Chief Technical Operations Officer)inMSMike Scott(Chief Development Officer)inRSRay Smith(Chief Financial Officer)in

Co-investorsANAngel ForumCICivilization Ventures Management, LlcINInBC Investment Corp.PAPage One VenturesPAPallasite VenturesPAPangaea Ventures Us Inc.+5 more

Bigfoot Biomedical develops a diabetes management system that combines continuous glucose monitor data with a doctor's instructions to give insulin dose recommendations.

Digital HealthHealthtechMedical DevicesNew York, US

Jeffrey Brewer(Executive Officer, Director)inBryan Mazlish(Executive Officer, Director)inJon Brilliant(Executive Officer)

Co-investorsWIWinklevoss CapitalXPXplorer CapitalJAJanus Henderson InvestorsSMSmile GroupVIVisionnaire Ventures, Llc

Biolinq develops a non-invasive glucose sensor that uses light to display glucose levels in real time, while also tracking activity and sleep to provide personalized health insights via a mobile app.

BiotechDigital HealthHealthtechMedical DevicesSan Diego, US

Jared Tangney(Executive Officer, Director, Promoter)inRichard Yang(Executive Officer, Director)Edward Kliphuis(Director)

BoardDBDaniel Bradbury(Director)inLGLana Ghanem(Director)

Co-investorsALAlpha Wave GlobalBEBeyond CapitalBIBioBritAPAphelion CapitalHIHikma VenturesLILifeSci Venture Partners+1 more

Code Biotherapeutics develops a proprietary non-viral 3DNA delivery platform for genetic medicines, RNAi, and other modalities, using targeting molecules to reach specific cells and tissues outside the liver.

BiotechDeep TechHealthtechHatfield, US

Lauren Kaskiel(Executive Officer)inRobert C. Getts(Executive Officer)BMBrian McVeigh(Executive Officer, Director)in

BoardDmitry Kuzmin(Director)Victor Stone(Director)Edward Mathers(Director)

Co-investorsNENew Enterprise Associates (NEA)4B4BIO CapitalAMAmgen VenturesHAHatteras Venture PartnersNONorthpond VenturesTATakeda Ventures+1 more

COUR develops antigen-specific immunotherapies that reprogram the immune system to treat the underlying causes of autoimmune and immune-mediated diseases while preserving normal immune function.

BiotechHealthtech

Co-investorsALAlpha Wave GlobalLULumira VenturesRORoche Venture FundANAngelini Ventures

Diasome develops metabolic therapies using its HDV platform to enable targeted drug delivery for treating diabetes, obesity, and metabolic diseases.

BiotechHealthtechMedical Devices

RGRobert Geho(Co-Founder, Chief Executive Officer)inW. Blair Geho(Co-Founder, Chief Scientific Officer)in

Co-investorsMEMedicxi

DiogenX is a preclinical-stage biotech company developing biologic therapeutics aimed at restoring insulin-producing beta cells for people with Type 1 diabetes.

BiotechDeep TechDigital HealthHealthtechMarseille, FR

BCBenjamin Charles(Co-Founder & CEO)inPCPatrick Collombat(Co-Founder & Scientific Advisor)inJean-Pascal Tranié(Co-Founder)in

Co-investorsADAdBio partnersRORoche Venture FundBOBoehringer Ingelheim Venture FundSUSunstone Capital

Egle Therapeutics develops targeted immunotherapy drugs by leveraging regulatory T cell (Treg) biology to treat autoimmune diseases and cancer.

Biotech

Fiorella Kotsias(Chief Scientific Officer)inBernard Vanhove(Chief Development Officer)in

BoardMDMichel Detheux(Chairman)in

Co-investorsEQEQT Life SciencesFUFund+

Eledon Pharmaceuticals is a clinical-stage biotechnology company developing immunology-based therapies, with a focus on protecting transplanted organs from rejection and treating autoimmune and neurodegenerative diseases including ALS.

AI & Machine LearningBiotechMedical Devices

Steven Perrin(President and Chief Scientific Officer)

Co-investorsBIBiotechnology Value FundNENewpath Partners

Enthera Srl is a privately held pharmaceutical company founded in 2016 and based in Milan, Italy.

BiotechHealthtechMilan, IT

Co-investorsSOSofinnova PartnersINIndaco Venture PartnersRORoche Venture FundABAbbVie

GentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases.

BiotechHealthtechMedical Devices

JBJane Buckner(Scientific Co-founder (President, Benaroya Research Institute))CPChandra Patel(Co-founder & SVP, Research and Development Operations)inDRDavid Rawlings(Scientific Co-founder and Senior Scientific Advisor)ASAndy Scharenberg(Scientific Co-founder, SAB Chair)AWAndy Walker(President and CEO)inTWTom Wickham(Chief Scientific Officer)

Co-investorsNONovartis Venture FundOROrbiMedRARA Capital

Biotechnology company developing safe and effective oral formulations of therapies traditionally limited to injections using ionic liquid technology

BiotechSaratoga, US

MMMitragotri Mitragotri(Executive Officer, Director)RSRavi Srinivasan(Executive Officer, Director)in

Co-investors7G7G BioVenturesSASanofi Ventures

Imtherapeutics develops oral therapies for Type 1 diabetes patients with specific genetic markers.

Biotech

Portfolio company acquired by Novo Nordisk for $1.1B USD.

Co-investorsAMAmorChemGEGenesys CapitalNENew Enterprise Associates (NEA)TATarnagulla VenturesADadMare BioInnovationsAMAmgen Ventures+2 more

Jaguar Gene Therapy develops gene therapy treatments for severe genetic diseases, focusing on AAV-based platform therapies designed to deliver one-time, long-lasting treatments.

BiotechHealthtechMedical Devices

JNJoseph Nolanin

Co-investorsAIAIFARARCH Venture PartnersDEDeerfield Management CompanyGOGoldman SachsSASamsung Ventures

Kriya provides working capital loans and business finance products to UK and European businesses, helping them manage cash flow, fund wholesale orders, and scale their buyer base.

FintechSaaS

ASAnil Stocker(Founder)in

Co-investorsMOMouro CapitalNONorthzoneBLBluebird VenturesFOForesite CapitalNANarya CapitalPAPatient Square Capital+2 more

Kriya Therapeutics is a biopharmaceutical company that develops and manufactures one-time gene therapies aimed at treating prevalent chronic diseases.

BiotechHealthtechMorrisville, US

SRShankar Ramaswamy(Co-Founder, Chairman & CEO)inRJRoger Jeffs(Co-Founder & Vice Chairman)inFWFraser Wright(Scientific Co-Founder & Chief Gene Therapy Officer)inSRShankar Ramaswamy, M.D.(Founder)inMSMichele Stone(Chief Scientific Officer)inKEKatherine Eade(Chief Legal Officer)

Co-investorsPAPatient Square CapitalPRPremji InvestAMAmplo VenturesBLBluebird VenturesFOForesite CapitalNANarya Capital+2 more

Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.

BiotechMedical Devices

MDMark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)CKCalvin Kuo(Scientific Co-Founder)KFKatie Fanning(President & Chief Executive Officer)in

Co-investorsARARCH Venture PartnersMRMRL Ventures FundONOno Venture Investment, Inc.PFPfizer Venture InvestmentsSOSofinnova PartnersALAlexandria+4 more

Protomer develops dynamic medicines that modify their activity in the body to increase potency where and when needed.

BiotechMedical DevicesPasadena, US

AMAlborz Mahdavi(CEO)in

Sanofi is a pharmaceutical company that discovers, develops, and delivers medicines and vaccines for patients globally.

BiotechHealthtechMedical Devices

Repertoire's Decode platform focuses on mapping the immune synapse — the interactions between T cell receptors, epitopes, and HLA molecules — to support the development of medicines targeting cancer and other diseases.

AI & Machine LearningBiotechDeep TechDigital HealthHealthtech

TSTorben Straight Nissen(Chief Executive Officer)inACAnthony Coyle(President, Research and Development)inRARobert Andtbacka(Chief Medical Officer)inJDJohn Delyani(Chief Business Officer)inJKJan Kisielow(Chief Scientific Officer, Repertoire Immune Medicines (Switzerland) Ltd.)in

Co-investorsFLFlagship PioneeringSOSoftBank Vision Fund

SAB BIO is a clinical-stage biopharmaceutical company developing multi-specific human immunoglobulin G (hIgG) therapies to treat and prevent immune and autoimmune disorders, using genetically engineered transchromosomic cattle to produce therapeutic candidates.

BiotechDigital HealthHealthtechMedical Devices

EJEddie J Sullivan(Founder)in

Sana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.

BiotechHealthtechMedical DevicesSeattle, US

RMRichard Mulligan(Director)inHBHans Bishop(Director)SHSteve Harr(President and Chief Executive Officer)JJJames J. MacDonald(Executive Officer)NHNathan Hardy(Executive Officer)

BoardGVGeoffrey von Maltzahn(Director)in

Co-investorsAMAmerican Family VenturesARARCH Venture PartnersF-F-Prime CapitalFLFlagship PioneeringINInnovating CapitalMAManta Ray Ventures+1 more

Cambridge, MA biotech developing stem cell-derived islet therapy plus an immune-protective device for type 1 diabetes; acquired by Vertex for $950M.

BiotechCambridge, US

Robert Millman(Executive Officer, Director)

BoardTFTodd Foley(Executive Officer, Director)inMitch Finer(Director)SKStephen Knight(Director)inJim Scopa(Director)William Sahlman(Director)

Co-investorsARARCH Venture PartnersF-F-Prime CapitalORORI CapitalSLSlater Technology FundEIEight Roads VenturesMPMPM BioImpact

Seraxis is a regenerative medicine company developing a replacement cell therapy for insulin-dependent (Type 1) diabetes, using engineered islet cells to replace those missing in patients.

BiotechHealthtechGermantown, US

WLWilliam L. Rust(Executive Officer, Director, Promoter)inCWCarole Welsch(Executive Officer)inGi-Hyeok Yang(Director)Roy Arup(Director)Bernie Treidl(Director)

BoardJNJames N. Topper(Director)

Co-investorsMAMaryland TEDCOTETEDCOFRFrazier Life Sciences

Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.

BiotechHealthtechMedical DevicesSouth San Francisco, US

JBJeffrey Bluestone(Executive Officer, Director, Promoter)in

BoardFan Yu(Director)Maggie Wilderotter(Director)Toni Hoover(Director)Terry Rosen(Director)Richard Klausner(Director)

Co-investors8V8VCARARCH Venture PartnersFRFrazier Life SciencesLALAVLILifeforce CapitalLILilly Asia Ventures+1 more

Zucara Therapeutics is a biotech company developing a once-daily therapeutic intended to prevent hypoglycemia (low blood sugar) in people with diabetes.

BiotechDigital HealthHealthtech

Co-investorsTOToronto Innovation Acceleration Partners

Orizuru Therapeutics develops cellular therapy products and regenerative medicine treatments utilizing iPS cell-related technology.

BiotechHealthtechMedical DevicesFujisawa, JP

Kenji Nonaka(代表取締役 (CEO))

Co-investorsKYKyoto University Innovation CapitalSMSMBC Venture CapitalSUSumitomo Mitsui Trust Bank